Timpani Capital Management LLC cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 12.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 34,105 shares of the company’s stock after selling 4,857 shares during the period. Omnicell accounts for about 1.3% of Timpani Capital Management LLC’s investment portfolio, making the stock its 27th biggest holding. Timpani Capital Management LLC owned 0.08% of Omnicell worth $2,757,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Parallel Advisors LLC acquired a new stake in Omnicell during the first quarter worth about $28,000. Nisa Investment Advisors LLC boosted its stake in shares of Omnicell by 125.0% in the first quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Omnicell in the fourth quarter valued at approximately $35,000. Manchester Capital Management LLC purchased a new position in shares of Omnicell in the first quarter valued at approximately $49,000. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in shares of Omnicell by 451.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 618 shares of the company’s stock valued at $38,000 after purchasing an additional 506 shares during the period. 97.32% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently commented on OMCL. BidaskClub lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a research note on Monday, April 29th. TheStreet downgraded shares of Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. Benchmark lifted their price target on shares of Omnicell from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, Craig Hallum downgraded shares of Omnicell from a “buy” rating to a “hold” rating and set a $84.00 price target for the company. in a research note on Friday, April 26th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $79.89.
NASDAQ:OMCL opened at $83.52 on Wednesday. Omnicell, Inc. has a fifty-two week low of $49.45 and a fifty-two week high of $86.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.47 and a current ratio of 1.96. The firm has a market cap of $3.44 billion, a PE ratio of 54.59, a P/E/G ratio of 2.60 and a beta of 1.14.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.23 by $0.38. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The business had revenue of $202.50 million for the quarter, compared to analyst estimates of $199.72 million. During the same period in the previous year, the firm earned $0.29 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, equities research analysts expect that Omnicell, Inc. will post 2.06 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Timpani Capital Management LLC Sells 4,857 Shares of Omnicell, Inc. (NASDAQ:OMCL)” was originally published by Tech Know Bits and is owned by of Tech Know Bits. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://techknowbits.com/2019/06/12/timpani-capital-management-llc-has-2-76-million-position-in-omnicell-inc-omcl.html.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.